Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)

• Status: RECRUITING
• Trial end date: 2027-07-31

Summary

This study is a prospective, single arm II clinical trial. The main objective of the study is to evaluate the efficacy and safety of the combination of Sacituzumab Tirumotecan (SKB264) and Tagitanlimab (KL-A167) in the treatment of AVPC (aggressive variant prostate cancer) and NEPC (neuroendocrine prostate cancer).

• Phase: PHASE2

Details

• Lead Sponsor: Tianjin Medical University Second Hospital
• Collaborator: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
• Treatments: 18-O-demethylcervinomycin A2